Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 925

1.

TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.

Jones RN, Moet GJ, Sader HS, Mendes RE, Castanheira M.

J Antimicrob Chemother. 2009 Apr;63(4):716-20. doi: 10.1093/jac/dkp021. Epub 2009 Feb 13.

2.

Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.

Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD.

Diagn Microbiol Infect Dis. 2009 Dec;65(4):404-13. doi: 10.1016/j.diagmicrobio.2009.10.001.

PMID:
19913683
3.

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.

Livermore DM, Mushtaq S, Warner M, Woodford N.

J Antimicrob Chemother. 2009 Apr;63(4):713-5. doi: 10.1093/jac/dkp002. Epub 2009 Jan 22.

4.

Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe).

Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ, Jones RN.

Clin Microbiol Infect. 2002 Dec;8(12):791-800.

5.

Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.

Ross JE, Anderegg TR, Sader HS, Fritsche TR, Jones RN.

Diagn Microbiol Infect Dis. 2005 May;52(1):53-8.

PMID:
15878443
6.

Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific.

Bell JM, Turnidge JD, Ballow CH, Jones RN; ZAPS Regional Participants.

J Antimicrob Chemother. 2003 Feb;51(2):339-45.

7.

A multicenter evaluation of linezolid antimicrobial activity in North America.

Ballow CH, Jones RN, Biedenbach DJ; North American ZAPS Research Group.

Diagn Microbiol Infect Dis. 2002 May;43(1):75-83.

PMID:
12052632
8.

Linezolid surveillance program results for 2008 (LEADER Program for 2008).

Farrell DJ, Mendes RE, Ross JE, Jones RN.

Diagn Microbiol Infect Dis. 2009 Dec;65(4):392-403. doi: 10.1016/j.diagmicrobio.2009.10.011.

PMID:
19913682
9.

Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.

Anderegg TR, Sader HS, Fritsche TR, Ross JE, Jones RN.

Int J Antimicrob Agents. 2005 Jul;26(1):13-21.

PMID:
15967640
10.

Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).

Fritsche TR, Sader HS, Stillwell MG, Jones RN.

Diagn Microbiol Infect Dis. 2009 Apr;63(4):440-6. doi: 10.1016/j.diagmicrobio.2009.01.019.

PMID:
19302928
11.

Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.

Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Peláez B, Andrade R, de la Torre MA, Fereres J, Sánchez-García M.

Clin Infect Dis. 2010 Mar 15;50(6):821-5. doi: 10.1086/650574.

12.
13.

Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.

Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN.

Diagn Microbiol Infect Dis. 2002 May;43(1):65-73.

PMID:
12052631
14.

Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods.

Muller-Serieys C, Drugeon HB, Etienne J, Lascols C, Leclercq R, Nguyen J, Soussy CJ.

Clin Microbiol Infect. 2004 Mar;10(3):242-6.

15.

Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).

Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.

J Antimicrob Chemother. 2006 May;57(5):914-23. Epub 2006 Mar 20.

16.

Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway.

Simonsen GS, Bergh K, Bevanger L, Digranes A, Gaustad P, Melby KK, Høiby EA.

Scand J Infect Dis. 2004;36(4):254-8.

PMID:
15198180
17.
18.

In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.

Schaadt R, Sweeney D, Shinabarger D, Zurenko G.

Antimicrob Agents Chemother. 2009 Aug;53(8):3236-9. doi: 10.1128/AAC.00228-09. Epub 2009 Jun 15.

19.

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.

Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2011 Aug;55(8):3684-90. doi: 10.1128/AAC.01729-10. Epub 2011 Jun 13.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk